Evusheld significantly protected against symptomatic COVID-19

Astra Zeneca says “Evusheld significantly protected against symptomatic COVID-19 for at least six months in PROVENT Phase III trial in high-risk populations.” https://www.astrazeneca.com/media-centre/press-releases/2022/evusheld-significantly-protected-against-symptomatic-covid-19-for-at-least-six-months-in-provent-phase-iii-trial-in-high-risk-populations1.html I’m glad I received the injections.  I’ve read that we will probably continue injections every 6 months while needed. I’ll be getting my next vaccine booster on Monday.  I was told to …
Source: beth's myeloma blog - Category: Cancer & Oncology Authors: Tags: Evusheld Source Type: blogs